|
|
- 2018
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted TherapyKeywords: alternative mechanisms of action, cost, persistence, rheumatoid arthritis, switching treatment, synthetic DMARD, treatment cycling, treatment persistence, tumor necrosis factor inhibitors Abstract: Targeted disease-modifying antirheumatic drug (DMARD) options for rheumatoid arthritis (RA) include tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) or alternative mechanisms of action (MOAs), such as a T-cell co-stimulation modulator (abatacept), Janus kinase inhibitor (tofacitinib), or interleukin-6 inhibitor (tocilizumab)
|
